arrow
O

Oren Meyers

AstraZeneca
H指数:12
被引数:553

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-Reported Outcomes In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Chemotherapy Plus Dostarlimab Or Placebo In The ENGOT-EN6-NSGO/GOG3031/RUBY Trial Over 3 Years Of Follow-Up

ENGOT-EN6-NSGO/GOG3031/RUBY试验中,接受化疗联合Dostarlimab或安慰剂治疗的原发性晚期或复发性子宫内膜癌患者三年随访的结局报告

2025-02-010
PRE
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab

来自比较一线化疗加dodstarlimab或pembrolizumab的随机II期PERLA试验的转移性非鳞状非小细胞肺癌患者的患者报告结局

2024-11-010
OAAI
Patient-reported outcomes (PROs) in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
2023-10-012
PRE